Regulation of PDGFC signalling and extracellular matrix composition by FREM1 in mice

DMM Disease Models and Mechanisms

Volumn 6, Issue 6, 2013, Pages 1426-1433

  Wiradjaja, Fenny ^a   Cottle, Denny L ^a   Jones, Lynelle ^a   Smyth, Ian ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; FRAS1 RELATED EXTRACELLULAR MATRIX PROTEIN 1 PROTEIN; METALLOPROTEINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR C; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL COMPOSITION; CELL STIMULATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROBLAST; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; LYMPHOKINES; MICE; NIH 3T3 CELLS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 84888869910     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.013748     Document Type: Article

References (31)

1. Aase, K., Abramsson, A., Karlsson, L., Betsholtz, C. and Eriksson, U. (2002). Expression analysis of PDGF-C in adult and developing mouse tissues. Mech. Dev. 110, 187-191.
2. Alazami, A. M., Shaheen, R., Alzahrani, F., Snape, K., Saggar, A., Brinkmann, B., Bavi, P., Al-Gazali, L. I. and Alkuraya, F. S. (2009). FREM1 mutations cause bifid nose, renal agenesis, and anorectal malformations syndrome. Am. J. Hum. Genet. 85, 414-418.
3. Campbell, J. S., Hughes, S. D., Gilbertson, D. G., Palmer, T. E., Holdren, M. S., Haran, A. C., Odell, M. M., Bauer, R. L., Ren, H. P., Haugen, H. S. et al. (2005). Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 102, 3389-3394.
4. Collins, C. A., Kretzschmar, K. and Watt, F. M. (2011). Reprogramming adult dermis to a neonatal state via epidermal activation of beta-catenin. Development 138, 5189-5199.
5. Cottle, D. L., McGrath, M. J., Cowling, B. S., Coghill, I. D., Brown, S. and Mitchell, C. A. (2007). FHL3 binds MyoD and negatively regulates myotube formation. J. Cell Sci. 120, 1423-1435.
6. Cottle, D. L., Kretzschmar, K., Schweiger, P. J., Quist, S. R., Gollnick, H. P., Natsuga, K., Aoyagi, S. and Watt, F. M. (2013). c-MYC-induced sebaceous gland differentiation is controlled by an androgen receptor/p53 axis. Cell Rep 3, 427-441.
7. Ding, H., Wu, X., Kim, I., Tam, P. P., Koh, G. Y. and Nagy, A. (2000). The mouse Pdgfc gene: dynamic expression in embryonic tissues during organogenesis. Mech. Dev. 96, 209-213.
8. Fredriksson, L., Li, H., Fieber, C., Li, X. and Eriksson, U. (2004). Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J. 23, 3793-3802.
9. Göhring, W., Sasaki, T., Heldin, C. H. and Timpl, R. (1998). Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. Eur. J. Biochem. 255, 60-66.
10. Goretzki, L., Burg, M. A., Grako, K. A. and Stallcup, W. B. (1999). High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan. J. Biol. Chem. 274, 16831-16837.
11. Grako, K. A. and Stallcup, W. B. (1995). Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. Exp. Cell Res. 221, 231-240.
12. Ivetac, I., Munday, A. D., Kisseleva, M. V., Zhang, X. M., Luff, S., Tiganis, T., Whisstock, J. C., Rowe, T., Majerus, P. W. and Mitchell, C. A. (2005). The type Ialpha inositol polyphosphate 4-phosphatase generates and terminates phosphoinositide 3-kinase signals on endosomes and the plasma membrane. Mol. Biol. Cell 16, 2218-2233.
13. Jadeja, S., Smyth, I., Pitera, J. E., Taylor, M. S., van Haelst, M., Bentley, E., McGregor, L., Hopkins, J., Chalepakis, G., Philip, N. et al. (2005). Identification of a new gene mutated in Fraser syndrome and mouse myelencephalic blebs. Nat. Genet. 37, 520-525.
14. Jinnin, M., Ihn, H., Mimura, Y., Asano, Y., Yamane, K. and Tamaki, K. (2005). Regulation of fibrogenic/fibrolytic genes by platelet-derived growth factor C, a novel growth factor, in human dermal fibroblasts. J. Cell. Physiol. 202, 510-517.
15. Kiyozumi, D., Sugimoto, N. and Sekiguchi, K. (2006). Breakdown of the reciprocal stabilization of QBRICK/Frem1, Fras1, and Frem2 at the basement membrane provokes Fraser syndrome-like defects. Proc. Natl. Acad. Sci. USA 103, 11981-11986.
16. Lai, K. K., Shang, S., Lohia, N., Booth, G. C., Masse, D. J., Fausto, N., Campbell, J. S. and Beretta, L. (2011). Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet. 7, e1002147.
17. Li, X., Pontén, A., Aase, K., Karlsson, L., Abramsson, A., Uutela, M., Bäckström, G., Hellström, M., Boström, H., Li, H. et al. (2000). PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat. Cell Biol. 2, 302-309.
18. McGregor, L., Makela, V., Darling, S. M., Vrontou, S., Chalepakis, G., Roberts, C., Smart, N., Rutland, P., Prescott, N., Hopkins, J. et al. (2003). Fraser syndrome and mouse blebbed phenotype caused by mutations in FRAS1/Fras1 encoding a putative extracellular matrix protein. Nat. Genet. 34, 203-208.
19. Petrou, P., Chiotaki, R., Dalezios, Y. and Chalepakis, G. (2007). Overlapping and divergent localization of Frem1 and Fras1 and its functional implications during mouse embryonic development. Exp. Cell Res. 313, 910-920.
20. Petrou, P., Makrygiannis, A. K. and Chalepakis, G. (2008). The Fras1/Frem family of extracellular matrix proteins: structure, function, and association with Fraser syndrome and the mouse bleb phenotype. Connect. Tissue Res. 49, 277-282.
21. Qiu, Q., Yang, M., Tsang, B. K. and Gruslin, A. (2004). EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction 128, 355-363.
22. Short, K. M. and Cox, T. C. (2006). Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding. J. Biol. Chem. 281, 8970-8980.
23. Short, K., Wiradjaja, F. and Smyth, I. (2007). Let's stick together: the role of the Fras1 and Frem proteins in epidermal adhesion. IUBMB Life 59, 427-435.
24. Singer, A. J. and Clark, R. A. F. (1999). Cutaneous wound healing. N. Engl. J. Med. 341, 738-746.
25. Smyth, I., Du, X., Taylor, M. S., Justice, M. J., Beutler, B. and Jackson, I. J. (2004). The extracellular matrix gene Frem1 is essential for the normal adhesion of the embryonic epidermis. Proc. Natl. Acad. Sci. USA 101, 13560-13565.
26. Soriano, P. (1997). The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 124, 2691-2700.
27. Stallcup, W. B. (2002). The NG2 proteoglycan: past insights and future prospects. J. Neurocytol. 31, 423-435.
28. Tallquist, M. D. and Soriano, P. (2003). Cell autonomous requirement for PDGFRalpha in populations of cranial and cardiac neural crest cells. Development 130, 507-518.
29. Vissers, L. E., Cox, T. C., Maga, A. M., Short, K. M., Wiradjaja, F., Janssen, I. M., Jehee, F., Bertola, D., Liu, J., Yagnik, G. et al. (2011). Heterozygous mutations of FREM1 are associated with an increased risk of isolated metopic craniosynostosis in humans and mice. PLoS Genet. 7, e1002278.
30. Vrontou, S., Petrou, P., Meyer, B. I., Galanopoulos, V. K., Imai, K., Yanagi, M., Chowdhury, K., Scambler, P. J. and Chalepakis, G. (2003). Fras1 deficiency results in cryptophthalmos, renal agenesis and blebbed phenotype in mice. Nat. Genet. 34, 209-214.
31. Yokose, U., Hachiya, A., Sriwiriyanont, P., Fujimura, T., Visscher, M. O., Kitzmiller, W. J., Bello, A., Tsuboi, R., Kitahara, T., Kobinger, G. P. et al. (2012). The endogenous protease inhibitor TIMP-1 mediates protection and recovery from cutaneous photodamage. J. Invest. Dermatol. 132, 2800-2809.